Esperion Therapeutis.Inc. buy Heureka
Start price
13.01.20
/
50%
€52.34
Target price
10.02.20
€110.00
Performance (%)
15.67%
End price
10.02.20
€60.54
Summary
This prediction ended on 10.02.20 with a price of €60.54. The prediction had a final performance of 15.67%. Heureka has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -7.696% | -7.696% | 107.767% | 60.683% |
| iShares Core DAX® | 0.444% | 3.030% | 12.677% | 49.790% |
| iShares Nasdaq 100 | 3.819% | 4.073% | 33.152% | 88.253% |
| iShares Nikkei 225® | 1.148% | 6.904% | 45.488% | 61.922% |
| iShares S&P 500 | 2.371% | 2.677% | 25.689% | 63.539% |
Comments by Heureka for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Kursziel geändert auf 110,0
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Heureka for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€56.00
26.02.20
26.02.20
€62.00
09.03.20
09.03.20
-30.14%
09.03.20
09.03.20
